Company Snapshot
- Ticker
- PFE
- Name
- PFE
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 150254550000.000000
- Volume
- 60,068,750
- Avg Volume (3M)
- 59,609,284
PFE
PFE
Last update recent
26.43
+0.58
(+2.24%)
Market Cap
150254550000.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 0.000000
- EPS
- 0.00
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 0.0%
- Net Income
- 0.000000
- Net Margin
- 0.0%
- Payout Ratio
- 0.0%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 0.00
- Forward P/E
- None
- P/S
- 0.00
- P/B
- 1.61
- Beta
- None
- Debt / Equity
- 0.66
- Current Ratio
- 1.28
- Return on Equity
- 0.00%
- Return on Assets
- 0.00%
Technicals & Returns
- Distance vs 200 DMA
- 10.74%
- 200 DMA
- 23.87
- Distance vs 50 DMA
- 6.06%
- 50 DMA
- 24.92
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The c Read more
- Name
- PFE
- Industry
- Drug Manufacturers - General
- CEO
- Dr. Albert Bourla D.V.M., Ph.D.
- Employees
- 88,000
- IPO Date
- 1972-06-01
- Phone
- 212 733 2323
- Address
- None
- Website
- https://www.pfizer.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Last Payout
2024-07-26 • $0.42
Latest News
Curated headlines from premium sources.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million
Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related …
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive's propr…
Cullen Capital Management LLC Has $88.32 Million Position in Pfizer Inc. $PFE
Cullen Capital Management LLC decreased its holdings in Pfizer Inc. (NYSE: PFE) by 22.9% in the second quarter, according to the company in its most recent 13F…
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?
Shares of Teva -- a generic-drug maker with a history of losses and high leverage -- have rallied strongly. Pfizer and Merck, which make branded drugs, are fin…
Forget Teladoc and Buy This Healthcare Stock Instead
Teladoc and Pfizer have both faced challenges over the past few years. While the latter has a clear path to recovery, the former doesn't seem to.